IgA Nephropathy clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
San Francisco, California and other locations
Our lead scientists for IgA Nephropathy research studies include Christopher Carlos.